Literature DB >> 20019103

MR imaging in multiple sclerosis: review and recommendations for current practice.

K-O Lövblad1, N Anzalone, A Dörfler, M Essig, B Hurwitz, L Kappos, S-K Lee, M Filippi.   

Abstract

MR imaging is widely used for the diagnosis and monitoring of patients with MS. Applications and protocols for MR imaging continue to evolve, prompting a need for continual reassessments of the optimal use of this technique in clinical practice. This article provides updated recommendations on the use of MR imaging in MS, based on a review of the trial evidence and personal experiences shared at a recent expert meeting of radiologists and neurologists.

Entities:  

Mesh：

Year:  2009        PMID： 20019103      PMCID： PMC7963928          DOI： 10.3174/ajnr.A1906

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  56 in total

1.  High-dose gadoteridol in MR imaging of intracranial neoplasms.

Authors:  V M Runge; J E Kirsch; V J Burke; A C Price; K L Nelson; G S Thomas; B L Dean; C Lee
Journal:  J Magn Reson Imaging       Date:  1992 Jan-Feb       Impact factor: 4.813

2.  Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

Authors:  Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2005-11       Impact factor: 6.016

3.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Authors:  Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

4.  Triple-dose versus single-dose gadoteridol in multiple sclerosis patients.

Authors:  L J Wolansky; J A Bardini; S D Cook; A E Zimmer; A Sheffet; H J Lee
Journal:  J Neuroimaging       Date:  1994-07       Impact factor: 2.486

5.  Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.

Authors:  D K Li; D W Paty
Journal:  Ann Neurol       Date:  1999-08       Impact factor: 10.422

6.  A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

Authors:  M Filippi; M Rovaris; R Capra; C Gasperini; T A Yousry; M P Sormani; F Prandini; M A Horsfield; V Martinelli; S Bastianello; I Kühne; C Pozzilli; G Comi
Journal:  Brain       Date:  1998-10       Impact factor: 13.501

7.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

8.  Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C.

Authors:  Thomas Frenzel; Philipp Lengsfeld; Heiko Schirmer; Joachim Hütter; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2008-12       Impact factor: 6.016

9.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

Authors:  Peter A Brex; Olga Ciccarelli; Jonathon I O'Riordan; Michael Sailer; Alan J Thompson; David H Miller
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

10.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

Authors:  L Kappos; D Moeri; E W Radue; A Schoetzau; K Schweikert; F Barkhof; D Miller; C R Guttmann; H L Weiner; C Gasperini; M Filippi
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321
View more
  31 in total

Review 1.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

2.  Accuracy of postcontrast 3D turbo spin-echo MR sequence for the detection of enhanced inflammatory lesions in patients with multiple sclerosis.

Authors:  J Hodel; O Outteryck; E Ryo; A-L Bocher; O Lambert; D Chéchin; H Zéphir; A Lacour; J-P Pruvo; P Vermersch; X Leclerc
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-07       Impact factor: 3.825

Review 3.  Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.

Authors:  Lesley J Scott
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

4.  MS lesions are better detected with 3D T1 gradient-echo than with 2D T1 spin-echo gadolinium-enhanced imaging at 3T.

Authors:  A Crombé; M Saranathan; A Ruet; M Durieux; E de Roquefeuil; J C Ouallet; B Brochet; V Dousset; T Tourdias
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-06       Impact factor: 3.825

Review 5.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

Review 6.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

7.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

Review 8.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 9.  Perfusion MRI: the five most frequently asked technical questions.

Authors:  Marco Essig; Mark S Shiroishi; Thanh Binh Nguyen; Marc Saake; James M Provenzale; David Enterline; Nicoletta Anzalone; Arnd Dörfler; Alex Rovira; Max Wintermark; Meng Law
Journal:  AJR Am J Roentgenol       Date:  2013-01       Impact factor: 3.959

10.  Synthesis and characterization of a novel gadolinium-based contrast agent for magnetic resonance imaging of myelination.

Authors:  Luca Frullano; Junqing Zhu; Robert H Miller; Yanming Wang
Journal:  J Med Chem       Date:  2013-02-18       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.